UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 2, 2007
Barrier Therapeutics, Inc.
(Exact name of registrant specified in its charter)
| | | | |
| Delaware | | 000-50680 | | 22-3828030 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
600 College Road East, Suite 3200, Princeton, New Jersey 08540
(Address of principal executive offices)
(609) 945-1200
(Registrant’s telephone number, including area code)
Not Applicable
(Former name and former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Section Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)). |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
| Item 1.01. | Entry into a Material Definitive Agreement. |
On March 6, 2007, Barrier Therapeutics, Inc. (the “Company”) issued a press release announcing it had entered into an agreement with Novartis Consumer Health, Inc. under which Novartis Consumer Health will promote the Company’s Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment to pediatricians in the U.S.
Beginning in May 2007, Novartis Consumer Health will initiate promotion of Vusion Ointment to pediatricians, supplementing the efforts of the Company’s 60-person sales force. Under the agreement which runs through 2008, the Company will pay Novartis a flat fee for each sales call made to a pediatrician. Responsibilities for the marketing and product strategy, as well as for the development, manufacture, distribution and sale of the product will remain with the Company.
The Company intends to file this agreement as an exhibit to its report on Form 10-K for the year ended December 31, 2006.
| Item 9.01 | Financial Statements and Exhibits. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | |
| | BARRIER THERAPEUTICS, INC. |
| | |
| Date: March 7, 2007 | | By: | | /s/ Anne M. VanLent |
| | Name: | | Anne M. VanLent |
| | Title: | | Executive Vice President, Chief Financial Officer and Treasurer |
